But is this medical-grade approach worth the cost, or just an expensive placebo
Symptoms range from rash and itching to severe anaphylaxis, swelling or breathing issues
Turns out I was using food to deal with a lot more than I realized
FDA Approves Dual Incretin Receptor Agonist for Type 2 Diabetes. (Approval Announcement, 2022) PubMed ID: 39632534 Tirzepatide for overweight and obesity management: Mechanism and 72-week clinical trial outcomes. FDA
Giugliano D, Longo M, Maiorino MI, Bellastella G, Chiodini P, Solerte SB, Esposito K
As demand for weight-loss drugs rises, states grapple with Medicaid coverage In January, the National Association of Medicaid Directors told the federal Centers for Medicare & Medicaid Services that state Medicaid departments had significant concerns over the fiscal impacts of the Biden proposal to require coverage of GLP-1s, and strongly recommend that CMS maintain the current state option to cover or not cover anti-obesity medications. But others say covering the drugs will yield long-term savings
